Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Anika Therapeutics (ANIK) EBIT Margin (2016 - 2026)

Anika Therapeutics has reported EBIT Margin over the past 17 years, most recently at 18.53% for Q1 2026.

  • Quarterly EBIT Margin fell 216.0% to 18.53% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 10.54% through Mar 2026, down 466.0% year-over-year, with the annual reading at 9.8% for FY2025, 554.0% down from the prior year.
  • EBIT Margin was 18.53% for Q1 2026 at Anika Therapeutics, down from 2.11% in the prior quarter.
  • Over five years, EBIT Margin peaked at 2.11% in Q4 2025 and troughed at 852.09% in Q4 2023.
  • The 5-year median for EBIT Margin is 11.62% (2025), against an average of 94.67%.
  • Year-over-year, EBIT Margin plummeted -56309bps in 2022 and then surged 84978bps in 2024.
  • A 5-year view of EBIT Margin shows it stood at 588.55% in 2022, then crashed by -45bps to 852.09% in 2023, then soared by 100bps to 2.3% in 2024, then surged by 192bps to 2.11% in 2025, then tumbled by -978bps to 18.53% in 2026.
  • Per Business Quant, the three most recent readings for ANIK's EBIT Margin are 18.53% (Q1 2026), 2.11% (Q4 2025), and 11.62% (Q3 2025).